Products and Platforms
Knopp’s most advanced R&D program is the development of dexpramipexole, a novel, oral investigational treatment for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease with limited treatment options.
The disruption of cellular bioenergetics has emerged as a common factor in pathways leading to cell death in ALS, Parkinson's, and other neurodegenerative disorders. Knopp is discovering novel small-molecule mediators of these pathways.
Ion channels, or proteins that regulate the excitability of cells, represent an important class of drug targets in several neurological and cardiovascular conditions. Knopp is discovering novel compounds to modulate these channels.
- Biogen Idec reports top-line results from Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis (ALS) January 3, 2013
- Knopp Biosciences Announces Recruiting of Key Scientific Executives and Completion of Laboratory Expansion May 2, 2012
- Data from Phase 2 Study of dexpramipexole in ALS published in Nature Medicine December 21, 2011